Clinical trials: Deprivation
Metastatic Hormone-Sensitive Prostate Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension
This study will assess the efficacy and safety of pembrolizumab plus enzalutamide plus Androgen Deprivation Therapy (ADT) versus placebo plus enzalutamide plus ADT in Chinese participants with mHSPC.
- Trial name
- NCT04934722
- Testing
- Pembrolizumab, Enzalutamide, Androgen Deprivation Therapy (ADT)
- Where
- 24 sites in China
- Volunteers
- 186 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Adenocarcinoma
Increasing the Dose of Survivorship Care Planning in Improving Care and Outcomes in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy
This trial studies how well increasing the dose of survivorship care planning improves care and outcomes in prostate cancer survivors receiving radiation therapy and androgen deprivation therapy.
- Trial name
- NCT03860961
- Testing
- Survivorship Care Plan, Treatment Plan
- Where
- 79 sites in United States
- Volunteers
- 550 people
- Sponsor
- NRG Oncology
Prostate Carcinoma
Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer
This phase II trial compares the effect of oxybutynin versus placebo for reducing hot flashes in men receiving androgen deprivation (hormone) therapy for the treatment of prostate cancer .
- Trial name
- NCT04600336
- Testing
- Oxybutynin Chloride, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 103 sites in United States
- Volunteers
- 88 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Adenocarcinoma of the Prostate, Stage II Prostate Cancer
Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer
This phase II trial studies the side effects and how well abiraterone acetate, prednisone, and leuprolide acetate or goserelin before and during radiation therapy works in treating patients with localized or locally advanced…
- Conditions
- Adenocarcinoma of the Prostate, Stage II Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- RAD1 (NCT01023061)
- Testing
- abiraterone acetate, prednisone, leuprolide acetate
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of Washington
Prostate Cancer
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen deprivation therapy (ADT) + TAK-700 versus ADT + bicalutamide.
- Trial name
- S1216 (NCT01809691)
- Testing
- TAK-700, Bicalutamide
- Where
- 560 sites in United States
- Volunteers
- 1,313 people
- Sponsor
- SWOG Cancer Research Network
Sleep Deprivation, Pain
Mechanisms of Sleep Disruption Hyperalgesia
Twenty percent of Americans suffer from chronic pain. Sleep disturbance is similarly prevalent and among the most common and disabling neurobehavioral problems associated with chronic pain.
- Trial name
- ESP2 (NCT01794689)
- Testing
- Morphine, Forced Awakenings, Uninterrupted Sleep
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Prostate Cancer, Prostate Neoplasms
Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer
Background: Metastatic castrate-sensitive prostate cancer is cancer that has spread beyond the prostate area. It can be controlled by lowering the amount of testosterone in the body.
- Conditions
- Prostate Cancer, Prostate Neoplasms, Neoplasms, Prostatic
- Trial name
- NCT02649855
- Testing
- PROSTVAC-V, PROSTVAC-F, Docetaxel
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Adenocarcinoma
Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer
The present study is a phase III randomized and multicentric trial evaluating the potential additional impact effect of two years adjuvant androgen deprivation when combined with neoadjuvant (4 months) and high-dose (76 Gy)…
- Trial name
- AADLPC (NCT02175212)
- Testing
- Short term androgen deprivation, Long term androgen deprivation
- Where
- Spain
- Volunteers
- 362 people
- Sponsor
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Advanced Prostate Cancer, Lower Urinary Tract Symptoms
Lucrin® Depot Efficacy and Safety Monitoring Study in Patients With Advanced Prostate Cancer and Lower Urinary Tract Symptoms (LUTS)
The purpose of the study is to determine the influence of GnRH (gonadotropin releasing hormone) analogue - Lucrin Depot 11.25 mg (Lucrin Depot 3.75mg - in Ukraine) administration on intensity of lower urinary tract symptoms…
- Trial name
- LEMON (NCT01078545)
- Testing
- Leuprolide acetate Depot Susp. 11.25 mg (Poland), 3.75 mg (Ukraine)
- Where
- 143 sites in Poland, Ukraine
- Volunteers
- 729 people
- Sponsor
- Abbott
Prostatic Neoplasms
Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy
The purpose of this study is to evaluate the efficacy, based on prostate-specific antigen (PSA) progression, of abiraterone acetate in participants with metastatic (spread of cancer cells from one part of the body to another)…
- Trial name
- NCT02217566
- Testing
- Abiraterone acetate, Prednisone, Androgen deprivation therapy (ADT)
- Where
- 4 sites in Brazil
- Volunteers
- 46 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer
Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therapy With Leuprorelin (Lucrin Depot) in Patients With Advanced Prostate Cancer (PCa) in Russia
The objective of this study was to describe treatment patterns of leuprorelin over 2 years using an intermittent, adjuvant regimen in participants with advanced prostate cancer (PCa)
- Trial name
- NCT01320735
- Volunteers
- 300 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Prostate Cancer
Med Diet Prevention Metabolic Syndrome Men Undergoing Androgen Deprivation Therapy Prostate Cancer
The purpose of this study is to assess for changes in a patient's overall energy level and well-being (quality of life) after 8 weeks of dietary intervention.
- Trial name
- NCT01083771
- Testing
- Olive Oil
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Brown University
Sleep Disturbance, Sleep Deprivation
Behavioral Sleep Intervention in Urban Primary Care: Aim 3
Investigators will enroll up to 120 parent-child dyads from Children's Hospital of Philadelphia (CHOP) urban primary care clinics.
- Conditions
- Sleep Disturbance, Sleep Deprivation, Sleep
- Trial name
- NCT04473222
- Testing
- Sleep Well!, Sleep education
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- Children's Hospital of Philadelphia
Prostatic Neoplasms
The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females
Background: Insomnia is associated with difficulty sleeping. The drug zolpidem is widely prescribed for insomnia. Women have reported worse effects from the drug than men.
- Trial name
- NCT03436745
- Testing
- Zolpidem, ECG
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Hot Flashes
Reproductive Health Survivorship Care Plan Pilot
Most young breast cancer patients undergo chemotherapy and/or endocrine therapy, treatments that impair ovarian function and result in significant reproductive health late effects.
- Conditions
- Breast Cancer, Hot Flashes, Vaginal Dryness, Estrogen Deprivation Symptoms
- Trial name
- NCT02176083
- Testing
- Text message management prompts
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- University of California, San Diego
Sleep Deprivation, Insufficient Sleep Syndrome
Pilot Study Comparing the Effectiveness of Two Different Methods of Acoustic Stimulation
This study is a randomized, single-blind, sham-controlled pilot cross-over trial comparing the feasibility, and efficacy of 2 nights of in lab use with active versus sham conditions in adults with sleep restricted schedules.
- Conditions
- Sleep Deprivation, Insufficient Sleep Syndrome, Healthy
- Trial name
- NCT03600194
- Testing
- PowerSleep Stim, Northwestern Stim
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Philips Respironics
Neoplasms, Prostate
Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy
Dutasteride inhibits the conversion of testosterone to dihydrotestosterone (DHT) the male hormone that leads to benign prostate growth.
- Trial name
- NCT00470834
- Testing
- dutasteride, bicalutamide
- Where
- 62 sites in United States, Canada
- Volunteers
- 127 people
- Sponsor
- GlaxoSmithKline
Prostate Cancer
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as steroid 17alpha-monooxygenase TAK-700, when used with other hormone therapy, may lessen the amount of androgens made by the body.
- Trial name
- NCT01546987
- Testing
- GnRH agonist, Anti-androgen, TAK-700
- Where
- 172 sites in United States, Canada
- Volunteers
- 239 people
- Sponsor
- Radiation Therapy Oncology Group
Castrate Resistant Prostate Cancer
Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer
This multicenter Phase I/II trial consists of two stages: a phase I stage in patients with castration resistant prostate cancer in which the recommended phase II dose will be determined for ipatasertib administered in combination…
- Trial name
- ADDItion (NCT04737109)
- Testing
- Ipatasertib, Darolutamide, Androgen Deprivation Therapy
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- David VanderWeele
Prostate Cancer
Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer
The addition of abiraterone acetate to standard treatment of radiotherapy and short-term androgen deprivation will increase the frequency of undetectable PSA.
- Trial name
- NCT01717053
- Testing
- Abiraterone acetate, Androgen deprivation, Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- Duke University